Medical Device News Magazine

Sunday, June 4, 2023



Contact us 561.316.3330

ENPICOM Secures Series B Funding

To scale up operations to meet the high demand for its antibody discovery SaaS Platform

ENPICOM, an innovative bioinformatics software engineering company, today announced closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO’s after launch in early 2021.

The additional funds enable the company to scale at a faster pace in this highly attractive market and continuing to deliver innovative product extensions for improved antibody discovery, characterization, and development.

ENPICOM’s IGX Platform is a powerful cloud solution designed to improve immunogenomics research by guiding the discovery and development of superior biotherapeutics. Tailored to the needs of scientists working in antibody discovery, it offers an intuitive environment to combine and manage sequencing data derived from state-of-the-art sequencing technologies (e.g., Sanger, bulk NGS, and Single Cell), integrate assay data from wet-lab experiments, and predict exposed sequence liabilities. All this information can be incorporated into tailored analysis workflows to support candidate selection and prioritization, and significantly improve efficiency and costs of early-stage R&D.

“We are thrilled with this capital injection to further grow our business. It clearly illustrates the trust of our existing investor group, BOM Brabant Ventures, NextGen Ventures, and Arches Capital, in our team and proposition. With the addition of BOP Capital, we have a great new strategic investor on board.” said Jos Lunenberg, Chief Executive Officer at ENPICOM.

“BOP Capital is very proud to join ENPICOM’s investor base. We believe in impact through technology. This is exactly what we see in ENPICOM’s platform. In combination with exceptional leadership and a strong execution track record, this provides a perfect setup to realize future growth in a highly promising market. We are looking forward to becoming part of their journey and work closely with the Enpicom team in the coming years.” said Jeroen Mensen, Managing Partner at BOP Capital.



Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy